Inhibition of the EGFR pathway leads to the down-regulation of pro-survival signals and up-regulation of pro-apoptotic molecules [12], by which EGFR tyrosine kinase inhibitors (EGFR-TKIs) exert their dramatic effects in patients with EGFR mutated lung cancer. The gene discussed is EGFR; the disease is lung cancer.